Skip to content
Screener

Sutro Biopharma STRO Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$63.7MBeat by $54.8M
EPS-$0.14Beat by $0.25
Revenue estimate$8.9M
EPS estimate-$0.39

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$13.6M
EPS estimate-$1.66

Financials

Q2 2025

Income statement

See full
Revenue$63.7M+148%
Operating income-$3.3M+93.1%
Net income-$11.5M+76.1%
EPS (diluted)-$1.35-129%

Balance sheet

See full
Cash & equivalents$64.0M-29.5%
Total debt$19.6M-26.1%
Total equity-$32.1M-121%
Total assets$262.4M-46.4%

Cash flow

See full
Operating cash flow-$44.7M—
Free cash flow-$44.7M—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$69.46M-70.8%
Enterprise value$25.03M-85.6%
P/S0.7×-0.7×

Profitability

See full
Operating margin-196.3%—
Net margin-199.8%—
FCF margin-238.8%—

Returns & leverage

See full
Current ratio3.1×-0.3×

Segments

By product

See full
Ongoing Performance Related To Unsatisfied Performance Obligations$50.4M+183%
Materials Supply$5.6M+2,769%
Financing Component On Unearned Revenue$832.0K-52.7%
Research And Development Services$609.0K-55.9%

FAQ

When did Sutro Biopharma report Q2 2025 earnings?
Sutro Biopharma (STRO) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Sutro Biopharma's Q2 2025 revenue and EPS?
Sutro Biopharma reported revenue of $63.7M and eps of $-0.14 for Q2 2025.
Did Sutro Biopharma beat estimates in Q2 2025?
Revenue beat the consensus estimate of $8.9M by $54.8M. EPS beat the consensus estimate of $-0.39 by $0.25.
How did Sutro Biopharma's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 148.0% from $25.7M a year earlier and eps grew 76.3% from $-0.59.
Where can I find Sutro Biopharma's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105159) and the 10-Q periodic report (0000950170-25-105219) directly on SEC EDGAR. The filing index links above go to sec.gov.